Evidence for this comes from recent studies showing that administration of l-DOPA, a precursor to the neurotransmitter dopamine clinically used to treat PD patients, in a mouse model of parkinsonism led to dopamine D1 receptor-mediated activation of the TOR pathway [81]. This evidence concerns the gene DRD1 and Parkinson disease.